LONDON, June 17 (Reuters) - The European Medicines Agency said on Tuesday that information about lung cancer should be added to the label for Pfizer Inc's inhaled insulin drug Exubera, due to increased cases in patients taking the product.
The move is no great surprise, since Pfizer and its partner Nektar Therapeutics announced in April that clinical trials had revealed a increased cancer rate.
That revelation dealt a final blow to Exubera, which had held the promise of letting diabetics avoid needles but proved a commercial flop. The European agency said Exubera was not expected to be available in the European Union after September 2008.
© 2022 Newsmax. All rights reserved.